-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, a number of Chinese herbal medicine companies have been "named"
.
For example, on August 17, the Anhui Provincial Food and Drug Administration issued an announcement saying that 7 companies of Chinese herbal decoction pieces (including formula granules) had project defects, 5 of which rectified within a time limit, and 2 companies suspended production, admonished, and interviewed; August On the 11th, the Sichuan Food and Drug Administration issued a notice on 6 batches of drugs that did not meet the requirements.
The six pharmaceutical companies that were "named" were all companies that produced Chinese herbal pieces; earlier in April, the Fujian Provincial Food and Drug Administration issued a notice.
It said that after supervising and sampling the drug quality of some drug production, operating enterprises and user units in the province, it was found that 4 batches of drugs did not meet the regulations.
Among them, a drug from a Chinese herbal medicine company entered the "black list"
.
Decoction pieces of traditional Chinese medicine are one of the three pillars of China's traditional Chinese medicine industry, and are also an important raw material for proprietary Chinese medicines.
They are supported by many favorable policies and are the "immunity" track of medical insurance.
The market for decoction pieces of traditional Chinese medicine is huge
.
According to the "2020 Economic Operation Report of China's Pharmaceutical Industry", the market size of Chinese herbal medicine decoction pieces processing market in 2020 will reach 178.
2 billion yuan
.
However, for a long time, the Chinese herbal medicine market has been faced with problems such as lack of unified classification standards, production specialization and low scale.
This is mainly due to the backward standards of some Chinese herbal medicines, unscientific cultivation of Chinese herbal medicines, and many small workshops with low prices and low quality.
The industry urgently needs to speed up the standardized and centralized development due to the inaccurate supervision methods and other reasons
.
In order to strengthen the management of drug quality, protect the safety and legitimate rights and interests of the public, and accelerate the high-quality development of the industry, China has successively issued a series of policies and measures in recent years, increasing the penalties for illegal operations
.
For example, according to the new version of the "Drug Administration Law", those who produce and sell inferior drugs shall have the illegally produced and sold drugs and their illegal income confiscated, and shall be fined not less than ten times but not more than twenty times the value of the illegally produced and sold drugs; .
If the value of wholesale medicines is less than 100,000 yuan, it shall be calculated as 100,000 yuan; if the value of illegal retail medicines is less than 100,000 yuan, it shall be calculated as 10,000 yuan; if the circumstances are serious, it shall be ordered to suspend production and business for rectification until the drug approval is revoked.
Certification documents, drug production license, drug business license or medical institution preparation license
.
The new version of the Pharmacopoeia has made another "heavy blow" on the Chinese herbal medicine industry
.
Part 4 0212 General Rules for the Verification of Medicinal Materials and Decoction Pieces stipulates: unless otherwise specified, the moisture content of decoction pieces should not exceed 13%; medicinal chips and impurities usually should not exceed 3%; the sulfur dioxide residue of medicinal materials and decoction pieces (except minerals) should not exceed 150mg/ kg; Prohibited pesticides (see the table below) for medicinal materials and decoction pieces (plants) shall not be detected (the limit of quantification shall not be exceeded)
.
Under the implementation of the new version of the Pharmacopoeia, it means that all plant-based Chinese medicinal materials and decoction pieces need to be tested for 33 pesticide residues
.
After years of rectification, the chaos in China's traditional Chinese medicine market has been reversed in recent years, and the quality has been steadily improved.
The national sampling inspection pass rate is close to 90%, which is consistent with the first-time inspection pass rate of the medicinal materials that enter the factory
.
For Chinese herbal decoction pieces enterprises, the industry believes that with layers of strict management and severe penalties, Chinese herbal decoction pieces enterprises can only go further if they abide by the norms.
Damage the reputation of the enterprise, and is not conducive to the sustainable development of the enterprise
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
For example, on August 17, the Anhui Provincial Food and Drug Administration issued an announcement saying that 7 companies of Chinese herbal decoction pieces (including formula granules) had project defects, 5 of which rectified within a time limit, and 2 companies suspended production, admonished, and interviewed; August On the 11th, the Sichuan Food and Drug Administration issued a notice on 6 batches of drugs that did not meet the requirements.
The six pharmaceutical companies that were "named" were all companies that produced Chinese herbal pieces; earlier in April, the Fujian Provincial Food and Drug Administration issued a notice.
It said that after supervising and sampling the drug quality of some drug production, operating enterprises and user units in the province, it was found that 4 batches of drugs did not meet the regulations.
Among them, a drug from a Chinese herbal medicine company entered the "black list"
.
Decoction pieces of traditional Chinese medicine are one of the three pillars of China's traditional Chinese medicine industry, and are also an important raw material for proprietary Chinese medicines.
They are supported by many favorable policies and are the "immunity" track of medical insurance.
The market for decoction pieces of traditional Chinese medicine is huge
.
According to the "2020 Economic Operation Report of China's Pharmaceutical Industry", the market size of Chinese herbal medicine decoction pieces processing market in 2020 will reach 178.
2 billion yuan
.
However, for a long time, the Chinese herbal medicine market has been faced with problems such as lack of unified classification standards, production specialization and low scale.
This is mainly due to the backward standards of some Chinese herbal medicines, unscientific cultivation of Chinese herbal medicines, and many small workshops with low prices and low quality.
The industry urgently needs to speed up the standardized and centralized development due to the inaccurate supervision methods and other reasons
.
In order to strengthen the management of drug quality, protect the safety and legitimate rights and interests of the public, and accelerate the high-quality development of the industry, China has successively issued a series of policies and measures in recent years, increasing the penalties for illegal operations
.
For example, according to the new version of the "Drug Administration Law", those who produce and sell inferior drugs shall have the illegally produced and sold drugs and their illegal income confiscated, and shall be fined not less than ten times but not more than twenty times the value of the illegally produced and sold drugs; .
If the value of wholesale medicines is less than 100,000 yuan, it shall be calculated as 100,000 yuan; if the value of illegal retail medicines is less than 100,000 yuan, it shall be calculated as 10,000 yuan; if the circumstances are serious, it shall be ordered to suspend production and business for rectification until the drug approval is revoked.
Certification documents, drug production license, drug business license or medical institution preparation license
.
The new version of the Pharmacopoeia has made another "heavy blow" on the Chinese herbal medicine industry
.
Part 4 0212 General Rules for the Verification of Medicinal Materials and Decoction Pieces stipulates: unless otherwise specified, the moisture content of decoction pieces should not exceed 13%; medicinal chips and impurities usually should not exceed 3%; the sulfur dioxide residue of medicinal materials and decoction pieces (except minerals) should not exceed 150mg/ kg; Prohibited pesticides (see the table below) for medicinal materials and decoction pieces (plants) shall not be detected (the limit of quantification shall not be exceeded)
.
Under the implementation of the new version of the Pharmacopoeia, it means that all plant-based Chinese medicinal materials and decoction pieces need to be tested for 33 pesticide residues
.
After years of rectification, the chaos in China's traditional Chinese medicine market has been reversed in recent years, and the quality has been steadily improved.
The national sampling inspection pass rate is close to 90%, which is consistent with the first-time inspection pass rate of the medicinal materials that enter the factory
.
For Chinese herbal decoction pieces enterprises, the industry believes that with layers of strict management and severe penalties, Chinese herbal decoction pieces enterprises can only go further if they abide by the norms.
Damage the reputation of the enterprise, and is not conducive to the sustainable development of the enterprise
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
